- Home
- DXLG vs TVRD Comparison
DXLG vs TVRD Comparison
Compare DXLG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | TVRD |
|---|---|---|
| Founded | 1976 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 27.5M |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DXLG | TVRD |
|---|---|---|
| Price | $0.65 | $1.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $1.50 | ★ $29.50 |
| AVG Volume (30 Days) | 66.9K | ★ 115.8K |
| Earning Date | 05-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.01 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $435,017,000.00 | $911,000.00 |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $0.44 | $1.50 |
| 52 Week High | $1.58 | $43.65 |
Technical Indicators
Market Signals| Indicator | DXLG | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 47.39 |
| Support Level | $0.62 | $1.72 |
| Resistance Level | $0.67 | $2.04 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 54.91 | 72.57 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.